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Heart disease is the leading cause of death worldwide. Within decades a limited process of cardiac cell regeneration was 
under observation. Embryonic stem cell (ESC) shows great potential for cell and tissue regeneration. Studies indicate that 
ESC has the potential to enhance myocardial perfusion and/or contractile performance in ischemic myocardium. However 
there is still challenge to evaluate the issues of teratoma. Then induced pluripotent stem cell was invented by introducing 
four transcriptional factors (Oct4, Sox2, Klf4, c-Myc). iPSC was created from murine fibroblast and then differentiated into 
cardiomyocyte. Reprogramming the adult cell could be performed in full, partial or direct reprogramming. Several studies 
add the significance by reprogramming the cells through more efficient techniques. However several limitations are still 
remained.
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Introduction
Heart disease in the form of ischemic heart disease and 
heart failure is the leading cause of death worldwide, with 
estimated >7 million death in 2012.1 Recent treatment 
strategy is to augment cardiac reperfusion so that can 
improve patient outcome and reduce morbidity due to 
heart failure, yet showing various efficacies.2 The loss of 
cardiac tissue diminish the properties of the heart to contract 
normally.3 The limited ability of human heart to regenerate, 
thus “regenerative medicine” represents as an alternative 
“second generation” treatment for ischemic heart disease.4 
This approach may encompass cardiomyocyte regeneration, 
neovascularization, and paracrine cytokines.3
 Adult heart is dominated by fibroblast and less 
population of cardiomyocyte. During a cardiac event 
or injury, fibroblast activation leads to fibrosis, which 
contribute to heart failure or conduction abnormalities.5 
Transplantation of different cells has been proposed to 
augment cardiac regeneration. The introduction of MyoD 
gene in fibroblast stimulated trans-differentiation into 
skeletal muscle.2 More recent work on cardiomyocyte 
regeneration has focused on cell originated from pluripotent 
embryonic stem cell (ESC)6 or induced pluripotent stem 
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cell (iPSC)7,8 and adult progenitor cell located in the heart 
termed as resident cardiac progenitor cells (CPC) or in non 
cardiac-sites (non-resident CPC).
 This review will discuss various cardiac cell 
reprogramming, initially iPSC, a method to reprogram 
somatic cell into pluripotent stem cell,7 then partial 
reprogramming through CPC,9 and direct reprogramming 
method which aim to directly convert the mature (unipotent) 
fibroblast to cardiomyocyte without going through iPSC 
type.10 Furthermore we will discuss the benefit and future 
use of cardiac reprogramming in heart disease.
Cardiomyocyte regeneration
Several vertebrae like axolotl,11 zebrafish and newt,12 
are evident to have significant regeneration capacity of 
the heart. This ability is also found transiently in mice 
during the first week of their live.13 Shortly after birth, 
human myocardium growth transition from hyperplastic 
to hypertrophic phase, characterized by the presence of 
binucleated cardiomyocyte. Indicating the cardiomyocyte 
differentiation already terminated.14 However this concept 
has been changed recently, 14C was used to carbon date the 
DNA of proliferating cardiomyocyte. Limited regeneration 
of human cardiomyocyte from pre-existing cardiomyocyte 
was confirmed, approximately 1% per year and 0.4% 
per year at age 20 and 75 respectively.15 A similar rate 
of cardiogenesis in young human adults was recently 
confirmed (1.9% at 20 years) and declined after 20 years old 
with the loss of cytokinetic ability.16 Based on this, about 
45% would be renewed over the normal human lifespan and 
more significance in woman compare to male population, 
15 to 11 times cardiomyocyte turnover respectively.17  
Cardiopoesis and self-generating cells
The natural response for cardiac tissue damage is 
reinforcement of stem cells programming to lineage-
specifying cardiovascular-derived defined as cardiopoiesis.18 
Cardiopoiesis guides stem cells to re-activate cellular 
plasticity, re-engage into cardiovasculogenesis, and re-set an 
active propensity for repair. Many type of stem cells already 
tested to measure their ability to regenerate: adult cells 
(umbilical cord blood mononuclear cell,19-21 bone marrow-
derived mesenchymal stem cell,22,23 resident or endogenous 
cardiac stem cell,24 endothelial progenitor cell25-28); and 
ESC or iPSC which shows great potentials.7,29 Preliminary 
studies indicate that ESC has the potential to enhance 
myocardial perfusion and/or contractile performance in 
ischemic myocardium. However there is still challenge to 
evaluate the issues of teratoma22 and what actually drives 
the improvement of cardiac function after the application 
ESC.30 In the other hand to maintain cardiopoesis, small 
molecules in the form of growth factors or cytokines such as 
fibroblast growth factor (FGF), vascular endothelial growth 
factor (VEGF), erythropoietin (EPO) or granulocyte colony 
stimulating factor (G-CSF) also introduced to enhance the 
mobilization of progenitor cells.27-29 
Novel cell sources “cardiomyocyte from ESC 
or iPSC”
ESC is undiffentiated, pluripotent and self-renewing cell 
in appropriate culture condition, which give rise to three 
embryonic germ layers. The gene expression of ESC-
derived cardiomyocyte resembles mammalian heart and 
become mature with time.31 In order to reduce immune graft 
rejection, generation of allogeneic patient-specific cells are 
warranted. 
 A novel approach with four transcription factors 
Oct4, Sox2, Klf4 and c-Myc create ESC-like cells or iPSC. 
Development to reprogram cardiomyocyte from omnipotent/ 
adult cells could be performed in three strategies (Figure 1)32: 
1. Full reprogramming of the iPSC and subsequent cardiac 
differentiation. 2. Partial reprogramming of fibroblast to 
cardiac progenitor cells and subsequent differentiation, and 
3. Direct reprogramming into cardiomyocyte.2,32 Generated-
cardiomyocte can be cultivated ex-vivo than transplanted 
into infarcted tissue or induction of cardiomyocyte in vivo 
with various recognized transcription factors or microRNA 
(miR).
Full reprogramming
ESC is known to reliably give rise to cardiomyocyte in vitro. 
This pluripotent cell can be propagated in undiffentiated state 
and then coaxed to variety of cell lineages.33 Nevertheless, 
the inability to create patient- or disease-specific ESC 
from adult individual and immune rejection-associated 
with allogeneic cell transplant raise the limitation when 
translated to clinical use. 
 The introduction of four transcription factors7,34 
become the major revolution in regenerative medicine. This 
strategy required full reprogramming of fibroblasts into 
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iPSCs, and subsequent differentiation to cardiomyocyte, 
which take a long period (months). Functional analyses 
of iPSC-derived cardiomyocyte demonstrate that they are 
embryonic or immature cardiomyocyte rather than adult 
type cardiomyocyte.32 At present cardiomyocyte derived 
from human iPSC is used for disease modeling. 
Partial reprogramming
One of the limitations in using the iPSC approach is 
the duration, which may take a few months to complete 
the processes including fibroblast expansion and 
reprogramming, expanding the generated iPSC colonies, 
and finally differentiate into the cardiac lineage.7 To 
overcome this limitation, overexpression of Oct4, Sox2, 
and Klf4, c-Myc in murine fibroblast was performed in 
short incubation period with cardio-inductive medium by 
adding growth factor bone morphogenetic protein (BMP)4 
and an inhibitor of Janus kinase (JAK) to further prevent 
development of pluripotent lineage.9 Using this strategy 
cardiomyocyte generation can be shortened within 11-
12 days. However, it is still unrevealed how the partially 
reprogrammed cardiomyocyte compare with those 
derived from pluripotent stem cell lines, in terms of their 
cardiomyocyte phenotypic properties and their capacity for 
cardiac repair. 
Direct reprogramming 
Direct reprogramming fibroblast into induced 
cardiomyocyte (iCM) can be performed by adding some 
combination of gene specific transcription factors (Gata4, 
Mef2c, Tbx5, Hand2, Myocd, etc.) into cardiac fibroblast, 
tail tip fibroblast (TTF) or mouse embryonic fibroblast 
(MEF). These transcription factors were introduced using 
viral vectors (retroviruses, lentiviruses, adenoviruses, etc.); 
or lipofection method to transfect cells with cardiac specific 
miR.32 iCM can be produced by adding a combination of 
three developmental transcription factors (Gata4, Mef2c, 
Tbx5)10 or four transcription factors (Gata4, Mef2c, Hand2, 
Tbx5).35 However evaluation to suitable iCM is still 
remained a challenge. Interestingly, combination of Mef2c, 
Tbx5, Myocd, resulted in a more developed cardiomyocyte.36
 When translated in vivo, the application of Gata4, 
Mef2c, Tbx5 in vivo in 2 month infarcted mice using 
retroviral, showed a decreased infarct size and improvement 
in cardiac function.37 Transduction with retroviruses contain 
four transcription factors Gata4, Hand2, Mef2c Tbx5 to 
cardiac fibroblast in vivo showed an increase of iCM like cell 
(9.2%), almost 4-fold higher compared with Gata4, Mef2c, 
Tbx5 (2.5%).35 In addition, in vivo iCMs express more fully 
reprogrammed than their in vitro counterparts, suggest an 
unrevealed factors that enhance reprogramming.35,37
 The potential of miR for differentiating pluripotent 
stem cells to cardiovascular lineage was recognized.38 By 
introducing miR (miR-1, miR-133, miR-208, and miR-499) 
into neonatal cardiac fibroblasts, iCMs could be resulted 
directly in vitro and in vivo. Application of miR was 
enhanced by JAK inhibitor treatment. The miR-mediated 
induction found to be safer for applications in humans.39 
Compared with Gata4, Mef2c, Tbx5 merely, miR and Gata4, 
Mef2c, Tbx5 combination produce 7-fold beating iCMs and 
shorten the duration in inducing beating cells.40
From translational research to human 
application in vivo
There were three studies in direct reprogramming of 
fibroblasts.41-43 Combination of four transcription factors 
(Gata4, Hand2, Tbx5, and Myocd) and two muscle-specific 
miRs (miR-1 and miR-133), could reprogram up to 20% 
of fibroblast into cTnT+ cells. Furthermore, a subset of 
iCMs demonstrated spontaneous beating after 11 weeks 
in culture.43 Similarly, a mixture of seven transcription 
factors (Gata4, Mef2c, Tbx5, Mesp1, Myocd, Zfpm2, 
Figure 1. Three different pathways of emerging cardiomyocyte 
regeneration which include a full reprogramming approach 
(purple line), a partial reprogramming approach (orange line), 
and a direct reprogramming approach (green line).32 (Adapted 
with permission from International Heart Journal).
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Esrrg) gene expression in fibroblasts lead to iCM.42 This 
work demonstrated that this mixture of reprogramming 
factors made human iCMs epigenetically stable, and that 
transforming growth factor (TGF)-β signaling improved 
the efficiency of human iCMs reprogramming.42 Finally, 
iCMs resulted from reprogramming human fibroblast with 
a combination of five transcription factors (Gata4, Mef2c, 
Tbx5, Mesp1, Myocd) demonstrated action potentials and 
beating when co-cultured with rat cardiomyocyte.41 Besides 
all stated transcription factor, ETS-2 was also used in 
combination with Mesp1 for fibroblast treated with activin 
A and BMP2 to reprogram human dermal fibroblasts into 
cardiac progenitor-like cells, which can differentiate into 
iCMs.44 Despite these promising features, direct cardiac 
reprogramming is less efficient in human cells compared to 
murine fibroblasts. An optimized combination of appropriate 
transcription factors and miRs for direct human cardiac 
reprogramming is required, as well as preconditioning for 
human cardiomyocyte. 
Future issues and challenges
Reprogramming process though promising still lead 
with several limitations especially in terms of teratoma 
formation,32 differentiation efficiency, the specificity of 
cardiomyocyte phenotype,34 long term survival of the 
cells and immune graft rejection.45 Many factors are yet to 
be revealed in favor to generate efficient reprogramming. 
Applying hypoxic environment or directly introduce 
in vivo are reported to increase the possibility of new 
cardiomyocyte.46 Further research and validation of methods 
are necessary. 
Conclusion
Through full, partial or direct reprogramming, adult 
cardiomyocyte can be generated in vitro or in vivo by adding 
several transcriptional factors. Many limitation considered 
regarding most efficient and standardization of protocols 
before translated to clinical practice. 
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